Log in or Sign up for Free to view tailored content for your specialty!
Immunodermatology News
Mount Sinai researcher explores keloid response to Dupixent
Preliminary findings from Emma Guttman-Yassky, MD, PhD, and colleagues demonstrate a novel use of dupilumab for managing chronic keloids with reductions in skin fibrosis and keloidal scarring, which may suggest a potential underlying Th2 pathogenesis in keloid formation.
Any smoking exposure in patients with lupus affects cutaneous manifestations
Researchers suggested there is a dose relationship between smoking exposure and cutaneous manifestations in systemic lupus erythematosus, which highlights the importance of smoking cessation to improve outcomes, according to a presentation at the American College of Rheumatology/Association of Rheumatology Professionals annual meeting.
Log in or Sign up for Free to view tailored content for your specialty!
Top five articles not to miss from ASDS annual meeting
Be sure to check out Healio Dermatology’s live coverage from the American Society for Dermatologic Surgery annual meeting.
Ruxolitinib cream improves repigmentation of vitiligo at 52 weeks
Among patients with vitiligo, treatment with ruxolitinib cream resulted in substantial improvements in total-body repigmentation at week 52 assessed by a 50% or more improvement from baseline in the total vitiligo area severity index, in a phase 2 study building upon previous data, according to data presented at European Academy of Dermatology and Venereology Congress.
UCB reports bimekizumab response rates superior to Stelara in psoriasis
Treatment with bimekizumab, an interleukin-17A and IL-17F inhibitor in adults with chronic plaque psoriasis, resulted in at least a 90% improvement in the Psoriasis Area and Severity Index and Investigator Global Assessment score of clear or almost clear, according to phase 3 results from the development program BE VIVID by UCB.
Bermekimab improves all disease measures of atopic dermatitis in phase 2 study
Bermekimab, which neutralizes interleukin-1 alpha, improved all disease measures of atopic dermatitis, including a large reduction in pruritus, according to phase 2 trial results presented at the European Academy of Dermatology and Venereology Congress by Alice Gottlieb, MD, PhD, of Icahn School of Medicine at Mount Sinai.
Oral JAK inhibitor improves alopecia areata severity
Patients with moderate to severe alopecia areata who were assigned to CTP-543, an oral Janus kinase inhibitor from Concert Pharmaceuticals, achieved a 50% relative reduction in Severity of Alopecia Tool score at 24 weeks, according to data presented at the European Academy of Dermatology and Venereology Congress.
4-year data demonstrate safety, efficacy of Ilumya in plaque psoriasis
The safety and efficacy of Ilumya were maintained after 4 years of treatment among patients with plaque psoriasis enrolled in the open-label reSURFACE1 trial, according to data presented at the European Academy of Dermatology and Venereology Congress.
Early diagnosis in systemic sclerosis key to limiting comorbidities
SAN DIEGO — Early screening and early diagnosis are critical to managing systemic sclerosis, according to a presentation at the 2019 Congress of Clinical Rheumatology West.
IBD risk increases with Enbrel therapy for other autoimmune diseases
Patients receiving Enbrel for inflammatory diseases other than inflammatory bowel disease have an increased risk for a diagnosis of Crohn’s disease or ulcerative colitis, according to study results.
-
Headline News
FDA warns of potential liver injury with Veozah for menopausal hot flashes
September 12, 20242 min read -
Headline News
Video games improved mental health during COVID-19 pandemic
September 12, 20242 min read -
Headline NewsSeptember 12, 20240 min read
-
Headline News
FDA warns of potential liver injury with Veozah for menopausal hot flashes
September 12, 20242 min read -
Headline News
Video games improved mental health during COVID-19 pandemic
September 12, 20242 min read -
Headline NewsSeptember 12, 20240 min read